Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Which has stronger earnings & valuation, VTRS or PFE?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	0.70	-$634.20M	-$3.17	-2.78
Pfizer	$63.63B	2.10	$8.03B	$1.38	17.02

Does the media prefer VTRS or PFE?

In the previous week, Pfizer had 76 more articles in the media than Viatris. MarketBeat recorded 79 mentions for Pfizer and 3 mentions for Viatris. Pfizer's average media sentiment score of 1.04 beat Viatris' score of -0.47 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	51 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Positive

Is VTRS or PFE more profitable?

Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-26.45%	16.20%	7.01%
Pfizer	12.62%	20.33%	8.53%

Do insiders & institutionals have more ownership in VTRS or PFE?

79.9% of Viatris shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is VTRS or PFE a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.3%. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more volatility and risk, VTRS or PFE?

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Do analysts rate VTRS or PFE?

Viatris currently has a consensus target price of $10.40, indicating a potential upside of 18.05%. Pfizer has a consensus target price of $28.28, indicating a potential upside of 20.38%. Given Pfizer's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Pfizer	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.50

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.